Tollywood actor Mahesh Babu secured an undisclosed minority stake in Shortgun Games to bolster its international development pipeline. The studio was established by Jeet Chandan and Vidhit Mehta to build globally competitive titles. Their inaugural project is designed specifically for PC and high-end consoles rather than mobile platforms. Founders anticipate completing and releasing their debut title globally before the close of 2028.
Key points
Tollywood actor Mahesh Babu acquired an undisclosed minority stake to support an Indian-o…: Tollywood actor Mahesh Babu acquired an undisclosed minority stake to support an Indian-origin global gaming franchise.
Project Takedown is targeted directly at major international gaming territories including…: Project Takedown is targeted directly at major international gaming territories including Japan, Europe, and the United States.
The studio's founders expect the flagship action-adventure title to launch by the end of…: The studio's founders expect the flagship action-adventure title to launch by the end of 2028.
Sources checked by our analysis pipeline: 1
Tollywood actor Mahesh Babu has picked up a minority stake in Mumbai-based gaming startup Shortgun Games for an undisclosed amount, backing the startup's ambition to build global PC gaming franchisee out of India.The startup, founded by Jeet Chandan and Vidhit Mehta, is developing its flagship title, Project Takedown, a 10-15-hour action-adventure game set in a near-future Mumbai. The game, designed exclusively for PC and modern console
Mahesh Babu picks up stake in gaming startup Shortgun Games
Synopsis
The startup, founded by Jeet Chandan and Vidhit Mehta, is developing its flagship title, Project Takedown, a 10-15-hour action-adventure game set in a near-future Mumbai. The game, designed exclusively for PC and modern console platforms, including PlayStation 5 and Xbox Series X|S, is primarily targeted towards international audiences, including the US, Europe and Japan. The founders expect the game to launch by 2028-end.
The consumer goods company capitalized on a steep drop in raw material costs to deliver its fastest operating profit surge in over a decade. This margin expansion allowed management to dramatically lift marketing investments and pull forward long-term revenue targets. However, mixed product volumes and lingering geopolitical and commodity risks will test the durability of this operational rebound.
Management has reaffirmed its strategic targets through 2026 as part of its ongoing operational roadmap. The continuity reflects underlying stability across the company's core operations during this planning period. Investors and stakeholders can anticipate continued adherence to these previously defined baseline commitments.
Under the terms being finalized, the Swiss healthcare manufacturing group is preparing to take ownership of multiple domestic facilities from the German science and technology firm. This operational transition shifts direct oversight of several key production hubs to an expanding contract development partner. The transaction directly alters the footprint of both pharmaceutical corporations across the North American market.